ArticleFrontiers in nutrition2026
Prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index in surgically treated non-small cell lung cancer.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The CALLY Index Is Associated with Overall Survival in Patients with De Novo Metastatic Gastric Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The C-reactive protein-albumin-lymphocyte (CALLY) index is a novel composite biomarker integrating systemic inflammation, nutrition, and immunity. It has shown prognostic value in various malignancies. However, its role in non-small cell lung cancer (NSCLC), particularly in surgically treated patients, remains uncertain. Therefore, we evaluated the prognostic value of the CALLY index in comparison with established prognostic markers in patients with resected NSCLC. Methods: We retrospectively analyzed 680 patients who underwent curative-intent surgery for NSCLC. The independent prognostic value of the CALLY index was assessed using Cox proportional hazards models, and its discriminative performance was compared with established inflammatory, nutritional, and immune markers using time-dependent receiver operating characteristic analysis. The optimal cut-off value was determined by maximally selected log-rank statistics based on overall survival (OS). Propensity score matching (PSM) was applied to balance baseline characteristics. OS and recurrence-free survival (RFS) were evaluated using Kaplan-Meier analyses. Stratified Cox analyses and interaction tests were performed by pathological stage and smoking status to evaluate effect consistency of the CALLY index. Results: The CALLY index yielded the highest area under the curve (AUC = 0.675) for predicting OS among the evaluated markers, indicating relatively better prognostic performance. The optimal cut-off value was 5.14. In multivariable Cox analyses, a high CALLY index remained independently associated with improved overall survival [hazard ratio (HR) 0.40, 95% confidence interval (CI) 0.26-0.64; Conclusion: The preoperative CALLY index is an independent and accessible prognostic biomarker for OS in resected NSCLC. It may serve as a practical tool for risk stratification, guiding postoperative surveillance and adjuvant treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.